Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:01:50.122Z.
Calculation as of: 2026-10-06T17:01:50.122Z.
Quote observation: 2026-10-06T16:59:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47fe9b5a4b5325aa2b63eefeab4e4f99d65252ab4bc117be38c834a5b01498bd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Coya Therapeutics, Inc.
Market Cap
$117.76M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $117.76M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.80M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.04M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.51M | N/A |
| Genelux Corporation (GNLX)vs › | $115.24M | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.27M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $113.02M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
